April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.» Read More
President-elect Barack Obama has proposed an ambitious plan to reform U.S. health care and get insurance for at least some of the 46 million Americans who now lack it.
Swiss Re, the world's second-biggest reinsurer, reported a surprise third-quarter net loss of 304 million Swiss francs ($263.2 million), hurt by investment losses.
The American International Group is rapidly running through $123 billion in emergency lending provided by the Federal Reserve, raising questions about how a company claiming to be solvent in September could have developed such a big hole by October, the New York Times reports.
That means, if you own the stock, it's time to cash out.
In general, traders and analysts agree that: 1) these insurers have very little short-term debt; 2) do not use much financial leverage; 3) they receive new dollars every day that need to be invested.
The head of the FDIC on Tuesday asked for an increase in premiums that will double the average paid by U.S. banks and thrifts next year to replenish the deposit insurance fund.
Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).
Amid the market melee, you may be starting to question the investment strategy behind your battered portfolio, but before you attempt any knee-jerk moves to mitigate risk, consider the impact an uber conservative investment stance might have on your ability to feather your nest egg.
As the Wall Street crisis unfolds, insurance policy holders might be asking themselves if the premiums they are paying for their coverage are going to do what are supposed to do: protect them from risk.
Okay, what were the chances that ImClone would get bought and Dendreon would come out with its interim test results on the same morning? Slim to none, I'd say. But that's exactly what the news gods had in store for two of the hottest names in biotech.
Turns out Wachovia's CEO was more hero than villian. It's just that Cramer didn't know until the Wells Fargo deal was announced.
Carmen and our team of experts answer your questions about bank failures, insurance and much more.
Citigroup and Wells Fargo were locked Sunday in a bidding war over a possible emergency takeover of Wachovia, the New York Times reported.
WaMu to JPMorgan. Now Wachovia to Citi? What all this bank-on-bank action means for your money, wherever it happens to be.
Carmen takes more questions after the show.
Carmen and our experts answer the questions you're probably wondering yourself about what to do to protect your money.
Insurance companies have gotten away from their core competencies and that is "dangerous," said New York State Insurance Superintendent Eric Dinallo.
Investing experts and economists worldwide weigh in on AIG and what this recent run of bailouts means for financial sectors across the globe.
Former Allstate CEO Edward Liddy will be the new CEO of AIG, which was rescued by an $85 billion loan from the Fed, in exchange for an 79.9% stake in itself.
What’s insured, what’s not, and what to do if you’re worried about your bank’s future.
Get the best of CNBC in your inbox